Logo image of KURA

KURA ONCOLOGY INC (KURA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KURA - US50127T1097 - Common Stock

9.84 USD
-0.01 (-0.1%)
Last: 12/19/2025, 8:00:02 PM
10.5699 USD
+0.73 (+7.42%)
After Hours: 12/19/2025, 8:00:02 PM
Fundamental Rating

3

Overall KURA gets a fundamental rating of 3 out of 10. We evaluated KURA against 531 industry peers in the Biotechnology industry. KURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KURA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KURA has reported negative net income.
KURA had a positive operating cash flow in the past year.
In the past 5 years KURA always reported negative net income.
KURA had negative operating cash flow in 4 of the past 5 years.
KURA Yearly Net Income VS EBIT VS OCF VS FCFKURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of KURA (-33.40%) is better than 63.91% of its industry peers.
KURA has a Return On Equity (-89.42%) which is in line with its industry peers.
Industry RankSector Rank
ROA -33.4%
ROE -89.42%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
KURA Yearly ROA, ROE, ROICKURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

KURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KURA Yearly Profit, Operating, Gross MarginsKURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

KURA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KURA has more shares outstanding
Compared to 5 years ago, KURA has more shares outstanding
The debt/assets ratio for KURA has been reduced compared to a year ago.
KURA Yearly Shares OutstandingKURA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KURA Yearly Total Debt VS Total AssetsKURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.23, we must say that KURA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.23, KURA is in line with its industry, outperforming 54.51% of the companies in the same industry.
KURA has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
The Debt to FCF ratio of KURA (0.12) is better than 95.86% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that KURA is not too dependend on debt financing.
KURA's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. KURA outperforms 42.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Altman-Z -1.23
ROIC/WACCN/A
WACC8.8%
KURA Yearly LT Debt VS Equity VS FCFKURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

KURA has a Current Ratio of 5.12. This indicates that KURA is financially healthy and has no problem in meeting its short term obligations.
KURA has a Current ratio of 5.12. This is comparable to the rest of the industry: KURA outperforms 56.77% of its industry peers.
A Quick Ratio of 5.12 indicates that KURA has no problem at all paying its short term obligations.
KURA has a Quick ratio (5.12) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.12
Quick Ratio 5.12
KURA Yearly Current Assets VS Current LiabilitesKURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

KURA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.08%.
EPS 1Y (TTM)-5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KURA will show a very strong growth in Earnings Per Share. The EPS will grow by 22.38% on average per year.
The Revenue is expected to grow by 144.26% on average over the next years. This is a very strong growth
EPS Next Y-31.54%
EPS Next 2Y-11.05%
EPS Next 3Y-8.91%
EPS Next 5Y22.38%
Revenue Next Year1380.16%
Revenue Next 2Y397.72%
Revenue Next 3Y163.01%
Revenue Next 5Y144.26%

3.3 Evolution

KURA Yearly Revenue VS EstimatesKURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
KURA Yearly EPS VS EstimatesKURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KURA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KURA Price Earnings VS Forward Price EarningsKURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, KURA is valued cheaper than 98.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.3
EV/EBITDA N/A
KURA Per share dataKURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

KURA's earnings are expected to decrease with -8.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.05%
EPS Next 3Y-8.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KURA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KURA ONCOLOGY INC

NASDAQ:KURA (12/19/2025, 8:00:02 PM)

After market: 10.5699 +0.73 (+7.42%)

9.84

-0.01 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners96.64%
Inst Owner Change0.01%
Ins Owners2.15%
Ins Owner Change11.88%
Market Cap856.28M
Revenue(TTM)104.03M
Net Income(TTM)-216.88M
Analysts82.86
Price Target33.66 (242.07%)
Short Float %9.45%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.03%
Min EPS beat(2)-60.23%
Max EPS beat(2)2.17%
EPS beat(4)2
Avg EPS beat(4)-14.36%
Min EPS beat(4)-65.56%
Max EPS beat(4)66.19%
EPS beat(8)5
Avg EPS beat(8)-6.44%
EPS beat(12)9
Avg EPS beat(12)-0.78%
EPS beat(16)13
Avg EPS beat(16)0.98%
Revenue beat(2)0
Avg Revenue beat(2)-54.91%
Min Revenue beat(2)-59.12%
Max Revenue beat(2)-50.69%
Revenue beat(4)2
Avg Revenue beat(4)105.75%
Min Revenue beat(4)-59.12%
Max Revenue beat(4)521.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.22%
PT rev (3m)22.22%
EPS NQ rev (1m)-10.66%
EPS NQ rev (3m)-6.55%
EPS NY rev (1m)-4.81%
EPS NY rev (3m)-3.58%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)35.14%
Revenue NY rev (1m)41.23%
Revenue NY rev (3m)48.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.23
P/FCF 10.3
P/OCF 9.75
P/B 3.53
P/tB 3.53
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-2.5
Fwd EYN/A
FCF(TTM)0.96
FCFY9.71%
OCF(TTM)1.01
OCFY10.25%
SpS1.2
BVpS2.79
TBVpS2.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.4%
ROE -89.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 79.89%
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Debt/EBITDA N/A
Cap/Depr 562.91%
Cap/Sales 4.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.12
Quick Ratio 5.12
Altman-Z -1.23
F-Score6
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)52.78%
Cap/Depr(5y)301.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.92%
EPS Next Y-31.54%
EPS Next 2Y-11.05%
EPS Next 3Y-8.91%
EPS Next 5Y22.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1380.16%
Revenue Next 2Y397.72%
Revenue Next 3Y163.01%
Revenue Next 5Y144.26%
EBIT growth 1Y-10.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.45%
EBIT Next 3Y-10.28%
EBIT Next 5Y1.83%
FCF growth 1Y170.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y175.01%
OCF growth 3YN/A
OCF growth 5YN/A

KURA ONCOLOGY INC / KURA FAQ

What is the ChartMill fundamental rating of KURA ONCOLOGY INC (KURA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KURA.


What is the valuation status for KURA stock?

ChartMill assigns a valuation rating of 2 / 10 to KURA ONCOLOGY INC (KURA). This can be considered as Overvalued.


Can you provide the profitability details for KURA ONCOLOGY INC?

KURA ONCOLOGY INC (KURA) has a profitability rating of 1 / 10.


Can you provide the financial health for KURA stock?

The financial health rating of KURA ONCOLOGY INC (KURA) is 6 / 10.